Wegovy
Facts
4 properties- Instance of
- trade name
- Subclass of
- pharmaceutical product[3]
- Has active ingredient
- semaglutide[4]
- Described at URL
- www.accessdata.fda.gov, www.bhf.org.uk
- RxNorm CUI
- 2553502
0 sources
Summary
Wegovy is a trade name[1].
high ≥ 0.90 · emerging ≥ 0.65 · low below — calibrated against hand-rated truth (single-source .44 · two-source .62 · production-typical .70), so a band is a measurement, not a promise. High is rare by design: it needs both a supported assertion and an evidence sentence. A confirmed or contradicted chip is a Wikidata cross-check; no chip means Wikidata has no value for that property — the ordinary case here, and it says nothing either way. A confirm-only note marks a property whose check can never disagree (Wikidata's border and capital data is not exhaustive), so silence there is a limit of the check, not of the claim.
evidence “Novo Nordisk received FDA approval for its weight-loss drug Wegovy in 2024 to lower heart risks in overweight or obese adults without diabetes.” tidende.dk · 2026-10-02 · read source
evidence “The study was funded by Novo Nordisk, the maker of the semaglutide drugs Ozempic and Wegovy, and several of the study’s researchers reported compensation from Novo.” everydayhealth.com · read source
Show 2 low-confidence claims
Published, not hidden — scoring low is not a reason to withhold a sourced claim. A contradicted chip means Wikidata holds a different value; both are shown so you can judge.
evidence “One pilot that researchers and providers are looking at is the new federal Medicare GLP-1 Bridge Program, a temporary project that seeks to bring down the cost of Zepbound, Wegovy and Foundayo to about $50 a month.” pleasantonweekly.com · read source
evidence “One pilot that researchers and providers are looking at is the new federal Medicare GLP-1 Bridge Program, a temporary project that seeks to bring down the cost of Zepbound, Wegovy and Foundayo to about $50 a month.” pleasantonweekly.com · read source